For those looking in, ASP is how medicare reimburses outpatient drugs. The physician practice buys the drugs up front, then bills Medicare the "average sales price" + 6%. The issue at hand is that Lucentis runs $2120 per injection. If you have a decent or large sized macular degeneration patient population, you'll be doing a lot of these injections. However, the number the practice collects is $320. Out of that number, you have to pay overhead / office staff / supplies etc.
The other thing to remember is that if it did include ASP reimbursement, ophthalmologists wouldn't be at the top, oncologists would. If a cancer doc saw 200 HER2 positive breast cancer patients in one year (16/month), treating them with Herceptin alone would cost $14,000,000. Most docs I've spoken to see 100-200 cancer patients per month (of course not all get treated with expensive drugs).
Unfortunately, I don't have a good source. The above is merely my speculation.
The physician fee is separate from these payments.